よむ、つかう、まなぶ。
2024年度の新型コロナワクチン定期接種に関する見解 (10 ページ)
出典
| 公開元URL | |
| 出典情報 | 2024年度の新型コロナワクチン定期接種に関する見解（10／21）《日本感染症学会》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
28.
Heath PT, et al. Safety and efficacy of the NVX-CoV2373 Coronavirus Disease 2019 vaccine at
completion of the placebo-controlled phase of a randomized controlled trial. Clin Infect Dis
76(3):398-407, 2023
29.
Alves K, et al. Immunogenicity of a fourth homologous dose of NVX-CoV2373. N Engl J Med
388(9):857-859, 2023
30.
Kuriyama K, et al. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019)
in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA
vaccine: Primary analysis report of a phase 3 open-label trial. Vaccine 41(25):3763-3771, 2023
31.
Kuriyama K, et al. One-year follow-up of the immunogenicity and safety of a primary series of the
NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II
randomized controlled trial. Vaccine 42(6):1319-1325, 2024
32.
独⽴⾏政法⼈医薬品医療機器総合機構. ヌバキソビッド筋注審査報告書（2022 年 4 ⽉ 19 ⽇）.
https://www.mhlw.go.jp/content/10906000/001174334.pdf. Accessed Aug 25, 2024.
33.
Liu Y, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Cell 184(13):3452-3466.e18, 2021
34.
独⽴⾏政法⼈医薬品医療機器総合機構. ダイチロナ筋注審査報告書（2023 年 7 ⽉ 31 ⽇）.
https://www.mhlw.go.jp/content/10906000/001174334.pdf. Accessed Aug 25, 2024.
35.
独⽴⾏政法⼈医薬品医療機器総合機構. ダイチロナ筋注審査報告書（2023 年 11 ⽉ 22 ⽇）.
https://www.mhlw.go.jp/content/10906000/001174334.pdf. Accessed Aug 25, 2024.
36.
Wayne CJ, et al. Self-amplifying RNA COVID-19 vaccine. Cell 187(8):1822-1822.e1, 2024
37.
Hoቹ NT, et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154
COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat Commun
15(1):4081, 2024
38.
Oda Y, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19
vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre,
randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis 24(4):351-360, 2024
39.
Oda Y, et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT154) versus BNT162b2. Lancet Infect Dis 24(4):341-343, 2024
40.
Oda Y, et al. Self-amplifying mRNA COVID-19 vaccine induces a superior immune response
compared with mRNA vaccine that persists to 12 months postvaccination. In: OPTIONS XII for the
control of Influenza. Brisbane, Australia; 2024.
41.
Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines:
Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25
Influenza Season. MMWR Recomm Rep 73(5):1-25, 2024
42.
CDC. CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus
Season.
https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html.
10
Heath PT, et al. Safety and efficacy of the NVX-CoV2373 Coronavirus Disease 2019 vaccine at
completion of the placebo-controlled phase of a randomized controlled trial. Clin Infect Dis
76(3):398-407, 2023
29.
Alves K, et al. Immunogenicity of a fourth homologous dose of NVX-CoV2373. N Engl J Med
388(9):857-859, 2023
30.
Kuriyama K, et al. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019)
in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA
vaccine: Primary analysis report of a phase 3 open-label trial. Vaccine 41(25):3763-3771, 2023
31.
Kuriyama K, et al. One-year follow-up of the immunogenicity and safety of a primary series of the
NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II
randomized controlled trial. Vaccine 42(6):1319-1325, 2024
32.
独⽴⾏政法⼈医薬品医療機器総合機構. ヌバキソビッド筋注審査報告書（2022 年 4 ⽉ 19 ⽇）.
https://www.mhlw.go.jp/content/10906000/001174334.pdf. Accessed Aug 25, 2024.
33.
Liu Y, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Cell 184(13):3452-3466.e18, 2021
34.
独⽴⾏政法⼈医薬品医療機器総合機構. ダイチロナ筋注審査報告書（2023 年 7 ⽉ 31 ⽇）.
https://www.mhlw.go.jp/content/10906000/001174334.pdf. Accessed Aug 25, 2024.
35.
独⽴⾏政法⼈医薬品医療機器総合機構. ダイチロナ筋注審査報告書（2023 年 11 ⽉ 22 ⽇）.
https://www.mhlw.go.jp/content/10906000/001174334.pdf. Accessed Aug 25, 2024.
36.
Wayne CJ, et al. Self-amplifying RNA COVID-19 vaccine. Cell 187(8):1822-1822.e1, 2024
37.
Hoቹ NT, et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154
COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat Commun
15(1):4081, 2024
38.
Oda Y, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19
vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre,
randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis 24(4):351-360, 2024
39.
Oda Y, et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT154) versus BNT162b2. Lancet Infect Dis 24(4):341-343, 2024
40.
Oda Y, et al. Self-amplifying mRNA COVID-19 vaccine induces a superior immune response
compared with mRNA vaccine that persists to 12 months postvaccination. In: OPTIONS XII for the
control of Influenza. Brisbane, Australia; 2024.
41.
Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines:
Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25
Influenza Season. MMWR Recomm Rep 73(5):1-25, 2024
42.
CDC. CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus
Season.
https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html.
10